Aurobindo Pharma Ltd vs Haleos Labs Limited Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 11, 2026

Key Highlights

The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1464 as of 11 Jun 15:30 . The P/E Ratio of Aurobindo Pharma Ltd changed from 9.7 on March 2021 to 19.3 on March 2025 . This represents a CAGR of 14.75% over 5 yearsThe P/E Ratio of Haleos Labs Limited changed from 11 on March 2021 to 16.2 on March 2025 . This represents a CAGR of 8.05% over 5 years The Market Cap of Aurobindo Pharma Ltd changed from ₹ 51653 crore on March 2021 to ₹ 67951 crore on March 2025 . This represents a CAGR of 5.64% over 5 yearsThe Market Cap of Haleos Labs Limited changed from ₹ 149.61 crore on March 2021 to ₹ 326.64 crore on March 2025 . This represents a CAGR of 16.90% over 5 years The revenue of Aurobindo Pharma Ltd for the Mar '26 is ₹ 8970 crore as compare to the Dec '25 revenue of ₹ 8833 crore. This represent the growth of 1.54% The revenue of Haleos Labs Limited for the Mar '26 is ₹ 77.15 crore as compare to the Dec '25 revenue of ₹ 94.97 crore. This represent the decline of -18.76% The ebitda of Aurobindo Pharma Ltd for the Mar '26 is ₹ 1867 crore as compare to the Dec '25 ebitda of ₹ 1896 crore. This represent the decline of -1.51% The ebitda of Haleos Labs Limited for the Mar '26 is ₹ 6.17 crore as compare to the Dec '25 ebitda of ₹ 14.23 crore. This represent the decline of -56.64% The net profit of Aurobindo Pharma Ltd changed from ₹ 918.22 crore to ₹ 920.84 crore over 8 quarters. This represents a CAGR of 0.14% The net profit of Haleos Labs Limited changed from ₹ 7.1 crore to ₹ 0.34 crore over 8 quarters. This represents a CAGR of -78.12% The Dividend Payout of Aurobindo Pharma Ltd changed from 7.53 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Haleos Labs Limited changed from 3.44 % on March 2021 to 2.12 % on March 2025 . This represents a CAGR of -9.23% over 5 years .

About Aurobindo Pharma Ltd

Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in December 1986 as a private limited company.
Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
APL is running with 29 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

About Haleos Labs Limited

SMS Lifesciences India Limited was incorporated originally as 'Potluri Real Estate Private Limited' on May 31, 2006.
The Company's name was changed to 'Potluri Packaging Industries Private Limited' on 6 November, 2013 and again changed to 'SMS Lifesciences India Private Limited on 4 August, 2014 to undertake the activities related pharma sector.
The Company became a wholly owned subsidiary Company of SMS Pharmaceuticals Limited w.e.f. 01.04.2016 and subsequently got converted into a Public Limited w.e.f. 22 June, 2016. The Company is engaged in the business of manufacturing and export of Active Pharma Ingredients(APIs) and their intermediates.
The Company is having manufacturing facilities at Kazipally and Jeedimetla, Hyderabad with an installed capacity of 65 KL. What started off as a single facility - single product manufacturing company in 1990 grew to be a multi-location group having products spread across an array of therapeutic segments.

FAQs for the comparison of Aurobindo Pharma Ltd and Haleos Labs Limited

Which company has a larger market capitalization, Aurobindo Pharma Ltd or Haleos Labs Limited?

Market cap of Aurobindo Pharma Ltd is 85,035 Cr while Market cap of Haleos Labs Limited is 408 Cr

What are the key factors driving the stock performance of Aurobindo Pharma Ltd and Haleos Labs Limited?

The stock performance of Aurobindo Pharma Ltd and Haleos Labs Limited is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aurobindo Pharma Ltd and Haleos Labs Limited?

As of June 11, 2026, the Aurobindo Pharma Ltd stock price is INR ₹1464.1. On the other hand, Haleos Labs Limited stock price is INR ₹1350.6.

How do dividend payouts of Aurobindo Pharma Ltd and Haleos Labs Limited compare?

To compare the dividend payouts of Aurobindo Pharma Ltd and Haleos Labs Limited, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.